Vermillion targets $31.5M from funding round

05/10/2013 | GenomeWeb Daily News (free registration)

Austin, Texas-based molecular diagnostics firm Vermillion hopes to raise as much as $31.5 million through the sale of 8 million shares of stock. Part of the proceeds will go toward improving sales and reimbursements for the company's OVA1 assay, which is used to distinguish malignant from benign ovarian tumors.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC